]i and NO levels were simultaneously monitored in the intact endothelium of freshly isolated bovine coronary arteries. Under control conditions, BK was found to increase NO production and [Ca 2ϩ ]i in parallel. When the arteries were pretreated with 100 nM human recombinant endostatin for 1 h, this BK-induced NO production was reduced by 89%, whereas [Ca 2ϩ ]i was unchanged. With the conversion rate of L- [ 3 H]arginine to L-[ 3 H]citrulline measured, endostatin had no effect on endothelial NO synthase (NOS) activity, but it stimulated ceramide by activation of sphingomyelinase (SMase), whereby O 2 Ϫ ⅐ production was enhanced in endothelial cells. O 2 Ϫ ⅐ scavenging by tiron and inhibition of NAD(P)H oxidase by apocynin markedly reversed the effect of endostatin on the NO response to BK. These results indicate that endostatin increases intracellular ceramide levels, which enhances O 2 Ϫ ⅐ production through activation of NAD(P)H oxidase. This ceramide-O 2 Ϫ ⅐ signaling pathway may contribute importantly to endostatin-induced endothelial dysfunction.
collagen; sphingolipid; free radicals; signal transduction; coronary artery ENDOSTATIN, originally purified from a murine hemangioendothelioma cell line, is a 20-kDa COOH-terminal fragment of NC1 domain of collagen ␣1 (XVIII), which is located in the basement membrane zones around blood vessels (27, 30) . Endostatin-forming domain NC1 is found in basement membranes, elastic fibers, and microfibrils of vessels and also in the embryonic skin and brain (24) . To date, endostatin has been reported as one of the most potent endothelial cell-specific inhibitors of angiogenesis and tumor growth in vivo (1, 5, 27) . On the cellular level, endostatin specifically inhibits proliferation and migration of endothelial cells and induces endothelial cell apoptosis (4, 27) . In addition to the action on endothelial cells, endostatin also regulates branching morphogenesis of renal epithelial cells and ureteric bud, inhibits pannus formation and bone destruction in rheumatoid arthritis animal models, and accumulates in amyloid plaques in Alzheimer's disease (3, 14, 19) .
Despite extensive studies on the action of endostatin on endothelial cell growth or apoptosis and related mechanisms, there are only a few studies done that addresses whether endostatin alters the function of cultured endothelial cells. So far little is known about the action of this angiostatic peptide on the intact endothelium on arterial wall and in vivo vasculature (29) . In this regard, a recent study reported that endostatin decreased vascular endothelium growth factor (VEGF)-induced activation of nitric oxide (NO) synthase (NOS) in cultured umbilical vein endothelial cells (34) . It has been suggested that endostatin may inhibit NO synthesis and thereby results in endothelial dysfunction (34) . On the other hand, in cultured aortic endothelial cells, endostatin has been reported to increase intracellular Ca 2ϩ concentrations ([Ca 2ϩ ] i ). Considering the stimulatory role of Ca 2ϩ in NO production in endothelial cells, these results raised two important questions: 1) Does endostatin decrease NO production but increase intracellular Ca 2ϩ concentrations? 2) What is the mechanism by which endostatin decreases NO in endothelial cells? Those previous studies did not answer these questions because they did not simultaneously measure intracellular Ca 2ϩ and NO concentrations. We recently developed a novel method that uses high-speed, wavelength-switching, fluorescence-imaging techniques to simultaneously in situ monitor intracellular NO and Ca 2ϩ concentrations in the intact coronary endothelium (37) . This assay system may be used to answer the questions listed above and to further explore the mechanisms mediating endostatininduced decrease in NO levels in arterial endothelial cells.
The present study hypothesized that endostatin uncouples endothelial NO production from increases in [Ca 2ϩ ] i in endothelial cells and that this uncoupling of Ca 2ϩ and NO response may be associated with enhanced O 2 Ϫ ⅐ production. To test this hypothesis, we simultaneously monitored intracellular NO and Ca 2ϩ levels in the intact endothelium of freshly dissected bovine coronary arteries and examined the effect of endostatin on bradykinin (BK)-induced increase in [Ca 2ϩ ] i and NO levels. We then determined the effects of endostatin on the activity of endothelial NOS and on the production of ceramide, an endothelial O 2 Ϫ ⅐-stimulating signaling lipid. Finally, we examined the effects of endostatin on NAD(P)H-dependent O 2 Ϫ ⅐ production and NO-O 2 Ϫ ⅐ interaction in the intact endothelium of these coronary arteries. [Ca 2ϩ ]i in the intact endothelium of coronary arteries. Recently, we developed a fluorescence imaging analysis to simultaneously monitor [Ca 2ϩ ]i with fura 2 as indicator and intracellular NO levels with 4,5-diaminofluorescein as a probe in the intact endothelium of freshly dissected small bovine coronary arteries (37) . It has been demonstrated that there is no interference between fura 2 and 4,5-diaminofluoroscein (DAF-2) signals in this assay system; therefore, DAF-2 signal is attributable to NO, which is not related with Ca 2ϩ signal (37) . This technique allows us to directly determine the relationship between [Ca 2ϩ ]i and NO levels in the endothelium, and the results obtained from these experiments more precisely represent the behavior of NOS and Ca 2ϩ in endothelial cells under physiological conditions. In brief, the arterial segment was cut open along its longitudinal axis and put into a recording chamber with the vessel lumen side downward facing the objective of an inverted microscope. Care was taken not to disrupt the endothelium. The chamber was filled with Hanks' buffered saline solution containing (in mM) 137 NaCl, 5.4 KCl, 4.2 NaHCO 3, 3 Na2HPO4, 0.4 KH2PO4, 1.5 CaCl2, 0.5 MgCl2, 0.8 MgSO4, 10 glucose, and 10 HEPES; pH 7.4. After a 30-min equilibration period, the artery was loaded with DAF-2 diacetate (10 M) and fura 2-AM (10 M) in Hanks buffer for 40 min at room temperature.
MATERIALS AND METHODS

Fluorescent imaging analysis of NO levels and
After dye loading was completed, temperature of the chamber solution was adjusted to 37°C by a temperature control system (Warner Instruments; Hamden, CT). An inverted microscope with epifluorescence attachments (Diaphot 200; Nikon, Tokyo, Japan) with a ϫ20 phase/fluor objective (Nikon Diaphot) was used to visualize individual endothelial cells on the endothelium of coronary arteries. The excitation light from a xenon lamp was filtered to provide wavelengths of 340 Ϯ 10, 380 Ϯ 10 (for fura 2), and 480 Ϯ 20 (for DAF-2) nm with a high-speed wavelength switcher (Lambda DG-4; Sutter, Novato, CA). Emission light from endothelial cells was passed through a dichroic mirror (500 nm) and through an emission filter of 510 Ϯ 20 nm for fura 2 or 535 Ϯ 25 nm for DAF-2 with a high-speed rotating filter wheel (Lambda 10 -2; Sutter). The fluorescence images were captured by a digital camera (SPOT RT Monochrome; Diagnostic Instruments). Metafluor imaging and analysis software (Universal Imaging) was used to acquire, digitize, and store the images and for off-line processing and statistical analysis. To reduce photobleaching of these fluorescent dyes, images with excitation of 340 and 380 nm for Ca 2ϩ were acquired at 2-s intervals, and images at excitation of 480 nm for NO were acquired at 10-s intervals. F340/F380, a fluorescence ratio of excitation at 340 nm to that at 380 nm, was determined after background subtraction, and [Ca -free (5 mM EGTA) solution, respectively; and ␤ is the fluorescence ratio at 380-nm excitation determined at Rmin and Rmax, respectively. The peak of Ca 2ϩ transient was used as the maximal Ca 2ϩ response. Intracellular NO production was expressed as relative fluorescence (f), which is the net increment of DAF-2 fluorescence at excitation/emission of 480/535 nm relative to its basal value (f ϭ ⌬F/F 0 ϫ 1,000), where F is DAF-2 fluorescence intensity obtained during experiments and F0 is its basal fluorescence intensity. Because NO does not dissociate from DAF-2 once this dye reacts with NO, the detected NO-sensitive fluorescence with DAF-2 primarily represents a cumulative amount of NO within the cells. To more representatively show the features of NO-DAF-2 fluorescence and to accurately present the relationship between NO production and Ca 2ϩ concentration in the cells, we performed a differential conversion of time-dependent NO-DAF-2 fluorescence curve to calculate NO production rate, df/dt using the following equation as described previously (37) (38, 39) . Briefly, the homogenates prepared from cultured bovine coronary endothelial cells (25 g protein) were incubated in 50-l reaction mixture containing the following (in mM): 25 Tris ⅐ HCl (pH 7.4), 0.6 CaCl2, 1 ␤-NADPH, 0.003 tetrahydrobiopterin, 0.001 flavin adenine dinucleotide, 0.001 flavin mononucleotide, and 0.005 cold L-arginine, along with 1.0 Ci L- [ 3 H]arginine in the absence or presence of endostatin. After incubation for 15 min at 37°C, the reaction was terminated by the addition of 400 l of ice-cold stop buffer containing the following (in mM): 50 HEPES (pH 5.5) and 5 EDTA. Equilibrated cation exchange resin was added to the samples, and they were then applied to spin columns. After centrifugation, the eluate (containing [ 3 H]citrulline) was collected, and the radioactivity was determined with a liquid scintillation counter. To determine the effect of endostatin on NOS activity in intact endothelial cells, the confluent endothelial cell cultures in 150-mm dishes were treated with endostatin for 60 min, followed by harvesting and homogenization. The formation of [ 3 H]citrulline was then assayed as described above. In these experiments, the formation rate of citrulline represented NOS activity, which was expressed as picomoles per minute per milligram protein.
Ceramide assay. Lipids from endothelial cells were extracted as we described previously (38) , and the lower chloroform phase was dried under N 2 and analyzed for ceramide concentration within 72 h. The dried lipids were solubilized into a detergent solution containing 7.5% n-octyl-D-glucopyranoside, and 5 mM cardiolipin in 1 mM diethylenetriaminepentaacetic acid solution, and then mixed with diacylglycerol kinase (Calbiochem) and 4 Ci [␥- 32 P]ATP to a final volume of 100 l. After incubation at 25°C for 3 h, the reaction was stopped by extracting the lipids with 600 l chloroform-methanol (1:1 vol/vol), 20 l 1% perchloric acid, and 150 l 1 M NaCl. The lower organic phase was recovered and dried with N 2. The 32 P-labeled ceramide (ceramide-1-P) was separated from other lipids by thin layer chromatography (TLC) with a solvent consisting of chloroform-acetonemethanol-acetic acid-water (10:4:3:2:1, vol/vol/vol/vol/vol). After visualization by autoradiography, the ceramide-1-P band was recovered by scraping and counted in a scintillation counter. The phosphorylation of C 6 ceramide as an internal control was determined in parallel. The identity of ceramide was confirmed by HPLC analysis as we reported previously (39) .
To determine the effect of endostatin on intracellular ceramide levels in endothelial cells, the confluent cell cultures in 150-mm dishes were treated with endostatin (100 nM) for 2, 5, and 30 min, followed by harvesting and homogenization. Fas ligand (Fas L, 100 ng/ml) was used as a positive control to stimulate ceramide production in all the experiments (11) .
SMase activity assay. To explore the mechanism for endostatinstimulated ceramide production, the activities of SMases, the major enzyme accounting for ceramide production, were determined as we reported previously (38) . Briefly, N-[methyl-
14 C]sphingomyelin was incubated with endothelial cell homogenates, and the metabolites of sphingomyelin, [ 14 C]choline phosphate, and ceramide were quantified. For acidic SMase (A-SMase), an aliquot of homogenates (20 g) was mixed with 0.02 Ci of N-[methyl- 14 C]sphingomyelin in 100 l acidic reaction buffer containing 100 mM sodium acetate and 0.1% Triton X-100, pH 5.0, and incubated at 37°C for 15 min. The reaction was terminated by adding 1.5 ml chloroform-methanol (2:1) and 0.2 ml double-distilled water. The samples were then vortexed and centrifuged at 1,000 g for 5 min to separate into two phases. A portion of the upper aqueous phase was transferred to scintillation vials and counted for the formation of (N-SMase), the activity was determined using the neutral reaction buffer containing 100 mM Tris ⅐ HCl, 5 mM MgCl2, and 0.1% Triton X-100; pH 7.5. The [ 14 C]choline phosphate (another product metabolized by SMase from sphingosine) formation rate (pmol ⅐ min Ϫ1 ⅐ mg protein Ϫ1 ) was calculated to represent the enzyme activity. To determine the effect of endostatin on SMase activity, the cells were treated with vehicle, endostatin (100 nM) for 2, 5, and 30 min, or Fas L (100 ng/ml) for 5 min, respectively.
Measurement of intracellular O 2 Ϫ ⅐ within the endothelium of small bovine coronary arteries. Intracellular O 2 Ϫ ⅐ was monitored by detecting dihydroethidium (DHE) fluorescence using the fluorescence imaging system described above. DHE can enter the cell and is fluorescent with excitation-emission of 380/435 nm in cell cytoplasm. DHE is oxidized specifically by O 2 Ϫ ⅐ to yield ethidium bromide (EtBr), which binds to DNA and has fluorescence at 480/610 nm excitationemission. The assays were performed on the endothelium of isolated small bovine coronary arteries as described above and previously (39) . Briefly, bovine arteries with the endothelium side up were incubated with 50 M DHE in Hanks' buffer for 30 -60 min at room temperature. Fluorescent images for EtBr and DHE were then captured and analyzed as described above. Previous studies in our laboratory have demonstrated that O 2 Ϫ ⅐ detected by DHE in this preparation was located in the endothelium (39) . O 2 Ϫ ⅐ fluorescence was measured every 1 min in a single area of the endothelial layer for 60 min. The ratio of EtBr and DHE fluorescence was recorded and calculated as the percent change relative to basal fluorescence ratio before stimulation. This ratiometric measurement of O 2 Ϫ ⅐ in the endothelial cell of intact arteries prevented the influence of differences in DHE loading levels on the sensitivity and specificity of the O 2 Ϫ ⅐ fluorescence assay (16, 25) .
Fluorescence spectrometric assay of O 2 Ϫ ⅐ production. A DHEbased fluorescence assay was used to assess O 2 Ϫ ⅐ production from NAD(P)H oxidase in endothelial cells (40) . Briefly, homogenates (20 g) freshly prepared from endothelial cells were incubated with DHE (100 M) and salmon testes DNA (0.5 mg/ml) in 200 l phosphatebuffered saline. Immediately before fluorescence was recorded, NADPH (final concentration 1 mM) was added, and ethidium-DNA fluorescence was measured using a fluorescence microplate reader (Series 4000, Applied Biosystems). Salmon test DNA was added to the reaction mixture to bind ethidium and amplify fluorescence signal. The ethidium fluorescence increase (arbitrary unit) was used to represent NAD(P)H oxidase activity as described previously (40) .
Statistics. Data are presented as means Ϯ SE. Significant differences between and within multiple groups were examined using ANOVA for repeated measures, followed by Duncan's multiple-range test. Student's t-test was used to evaluate the significant differences between two groups of observations. P Ͻ 0.05 was considered statistically significant.
RESULTS
Effect of endostatin on BK-induced NO production and Ca
2ϩ increase in bovine coronary arterial endothelium. Figure  1A presents some typical fluorescence images for endothelial Ca 2ϩ and NO response in coronary endothelium preparation. Under resting condition (without endostatin treatment), BK (1 M) significantly increased fura 2 fluorescence ratio (images taken before and 2 min after BK) in the intact endothelium, indicating a BK-induced increase in [Ca 2ϩ ] i . In parallel, BK increased DAF-2 fluorescence, which represented an increase in intracellular NO (images taken before and 5 min after BK). However, treatment of the endothelium with endostatin (100 nM) for 1 h had no significant effect on BK-induced changes in fura 2 fluorescence, but it blocked BK-induced increase in DAF-2 fluorescence (Fig. 1A) . The time course and relationship of BK-induced increases in [Ca 2ϩ ] i and NO levels in the endothelium are presented in Fig.  1B (n ϭ 7) . BK induced a transient increase in [Ca 2ϩ ] i from 90 Ϯ 2 nM to the maximal concentration at 371 Ϯ 48 nM in 2 min. This increase in [Ca 2ϩ ] i was accompanied by the increase in NO production in the endothelium as represented by NO production rate curve. This Ca 2ϩ dependence of NO production in the endothelium was described in detail in our previous study using this system (37) .
Next, we observed the effect of endostatin on this endothelial response to BK. Endostatin (10 -1,000 nM) did not acutely alter basal fura 2 fluorescence ratio or DAF-2 fluorescence in the endothelium or over a 60-min recording duration when added into the bath solution. As shown in Fig. 1C , a continuous recording of this endostatin-induced uncoupling of BK-induced NO production from increase in [Ca 2ϩ ] i was observed. It is clear that the pattern and extent of fura 2 fluorescence increase was similar to that observed before endostatin treatment (Fig. 1, C vs. B) . However, the increase in NO level under endostatin treatment was markedly attenuated. The endostatin concentration used in the present study is in the range of concentrations that has been reported to inhibit endothelial cell proliferation and migration and induce endothelial cell apoptosis (4, 27) .
The maximal responses of endothelial [Ca 2ϩ ] i and NO to BK and another stimulator of NO production with or without pretreatment of endostatin are presented in Fig. 2 . As summarized in Fig. 2A ] i (endostatin ϩ BK). Another receptorindependent endothelial NO stimulatory agonist A23187 (1 M) increased [Ca 2ϩ ] i by 5.3-fold and DAF fluorescence by 25-fold. Similar to BK, pretreatment of vessels with endostatin inhibited A23187-induced NO production, but it had no significant effect on the Ca 2ϩ response. These results were summarized in Fig. 2B .
Effect of endostatin on endothelial NOS activity. To explore whether endostatin-induced reduction of NO levels is associated with direct inhibition of NOS, we examined the effect of endostatin on NOS activity by measuring the conversion rate of 
Incubation of the cells with N
G -nitro-L-arginine methyl ester (L-NAME, 100 M) inhibited the formation of [ 3 H]citrulline by 95%. However, incubation of the cells with endostatin (100 nM, 60 min) had no significant effect on NOS activity (Fig. 3) .
Effect of endostatin on ceramide concentrations in endothelial cells.
Our previous studies demonstrated that ceramidemediated signaling pathway contributed to a decrease in NO bioavailability induced by different cell death factors such as TNF-␣ and Fas L (38) . Endothelial cells were stimulated with 100 nM endostatin, total lipids of the cells were then extracted, and the ceramide content was quantified. Figure 4A presents a typical TLC autoradiogram showing ceramide level measured as ceramide-1-P in endothelial cells under control conditions and after incubation with endostatin for different time period. Fas L (100 ng/ml), a typical stimulator of ceramide production, was used as a positive control. Endostatin produced a timedependent increase in endothelial ceramide. The basal ceramide concentrations in these cells were 5.2 Ϯ 0.2 nmol/mg protein (Fig. 4B ). Endostatin led a 31% increase in ceramide levels when the cells were treated for 30 min and was sustained for over 1 h incubation. This increase in ceramide was comparable to the increase caused by a 5-min incubation period of endothelial cells with Fas L.
Effect of endostatin on SMase activity in endothelial cells. Two different SMases, namely A-SMase and N-SMase, are involved in the ceramide production in endothelial cells (38) . Because endostatin induced an increase in endothelial ceramide, we examined the effect of endostatin on the activities of SMases. In cultured coronary endothelial cells, the basal activities for A-SMase and N-SMase, as measured by [ 14 C]choline formation rate, averaged 25.7 Ϯ 1.5 and 7.2 Ϯ 0.7 pmol ⅐min Ϫ1 ⅐mg protein Ϫ1 , respectively. As shown in Fig. 5A , endostatin rapidly increased A-SMase activity by 43% within 5 min, which was similar to that produced by 5 min Fas L stimulation. However, endostatin had no significant effect on N-SMase activity in these endothelial cells. Pretreatment of the endothelial cells with desipramine, an inhibitor of A-SMase, concentration dependently decreased endostatin-induced ceramide production in the endothelial cells. The ceramide increase was totally blocked at by 0.1 mM desipramine (Fig. 5B) . 
Effect of endostatin on O 2
Ϫ ⅐ production in the intact endothelium. We previously reported that ceramide is a potent activator of O 2 Ϫ ⅐ production associated with NAD(P)H oxidase. Increased O 2 Ϫ ⅐ production is an important mechanism mediating endothelial dysfunction. To provide direct evidence for the role of O 2 Ϫ ⅐ in the action of endostatin, the intracellular O 2 Ϫ ⅐ level was monitored in the endothelium of small coronary arteries. Figure 6A Ϫ ⅐ increase to a similar extent (tracing not shown). As shown in Fig. 6C , the maximal increase in O 2 Ϫ ⅐ production was significantly higher in endostatin-treated endothelium than control arteries. Tiron, desipramine, and apocynin blocked endostatininduced increase in O 2 Ϫ ⅐ production. The tiron and apocynin inhibitable endostatin-induced O 2 Ϫ ⅐ production corresponded to 60% of the maximal response of these endothelial cells to menadione sodium bisulfite (1 mM), which is a redox cycling compound reduced by complex I of the respiratory chain to generate superoxide and thereby was used as a positive control to increase intracellular O 2 Ϫ ⅐ level (8, 25) .
Effect of endostatin on NAD(P)H oxidase activity in endothelial cells.
To provide further evidence that endostatin activates NAD(P)H oxidase, endothelial cells were treated with endostatin (100 nM) for 2, 5, 15, and 30 min, before or after preincubated with different enzyme inhibitors. NADPH-dependent O 2 Ϫ ⅐ production was measured in homogenates. NAD(P)H oxidase-derived O 2 Ϫ ⅐ production significantly increased in endothelial cells pretreated with endostatin in a time-dependent manner, which was maximal at 30 min (from 272.7 Ϯ 39 to G -nitro-L-arginine methyl ester (L-NAME) was used as a negative control. *P Ͻ 0.05 vs. control. Fig. 4 . EST-induced increase in intracellular ceramide (Cer) levels in endothelial cells. A: representative autoradiograph of phospholipids fractionated by thin-layer chromatography (TLC) after diacylglycerol (DG) kinase assay. The bands represented ceramide-1-phosphate (Cer-1-P), which were from sample ceramide, and C6-ceramide-1-P (C6-Cer-1-P) from internal standard, respectively. B: summarized quantitative changes in Cer-1-P normalized to C6-Cer-1-P. The Cer-1-P and C6-Cer-1-P bands were scraped, and the radioactivity was counted using a liquid scintillation counter. *P Ͻ 0.05 vs. control (n ϭ 6). 535.3 Ϯ 59 arbitrary units). The increase in NAD(P)H oxidase activity was markedly inhibited by an A-SMase inhibitor desipramine and a NAD(P)H oxidase inhibitor apocynin (Fig. 7) .
Effect of O 2 Ϫ ⅐ scavenger and NAD(P)H oxidase inhibitor on endostatin-induced impairment in NO production. To determine whether endostatin-induced O 2 Ϫ ⅐ production contributes to blunted NO response to BK in the endothelium, the bovine coronary arteries were preincubated with the O 2 Ϫ ⅐ scavenger tiron (1 mM) for 15 min. Tiron alone had no effect on either basal or BK-induced increase in [Ca 2ϩ ] i or NO levels in the intact endothelium. As shown in Fig. 8A , preincubation of tiron did not alter [Ca 2ϩ ] i or NO levels in the presence of endostatin. However, it could restore the inhibitory effect of endostatin on BK-induced NO increase in these endothelial cells. Similar to Ϫ ⅐ levels in the endothelium. A: representative ethidium bromide (EtBr) fluorescence images in the endothelium taken under control conditions or after 60 min treatment with EST (100 nM). B: time course for the change in EtBr-to-DHE fluorescence ratio in the bovine arterial endothelium under control or incubation of EST in the absence or presence of a cell-membrane permeable superoxide dismutase (SOD) mimetic tiron (1 mM). C: summarized data showing the maximal ratio of EtBr-to-DHE fluorescence ratio at 60 min in the intact endothelium. Apocynin (100 M), a NAD(P)H oxidase inhibitor, was used to block NAD(P)H oxidase-mediated O 2 Ϫ ⅐ production in the presence of EST. Menadione (MEN, 1 mM) was used as a positive control in these experiments. *P Ͻ 0.05 vs. control. #P Ͻ 0.05 vs. EST. tiron, preincubation of apocynin (100 M, 15 min) could recover the NO response to BK in the presence of endostatin (Fig. 8B) .
DISCUSSION
In the present study, we examined the acute effect of endostatin on endothelial NO production and explored the mechanism by which endostatin reduces NO levels in the endothelial cells. Endostatin substantially reduced BK-induced NO increase in the intact endothelium of freshly dissected bovine coronary arteries. This effect of endostatin on endothelial NO levels was not accompanied by a decrease in [Ca 2ϩ ] i . The blockade of the NO response to BK by endostatin was not associated with the inhibition of basal NOS activity. Interestingly, we found that endostatin stimulated ceramide production through activation of A-SMase in these coronary endothelial cells, which increased O 2 Ϫ ⅐ production and thereby decreased NO levels in the endothelium.
Endostatin had no effect on basal [Ca 2ϩ ] i or NO levels in the intact endothelium. However, pretreatment of the arteries with endostatin for 1 h substantially reduced BK-induced NO increases. This inhibitory effect of endostatin was observed while [Ca 2ϩ ] i increased. It appears that an uncoupling of BK-induced [Ca 2ϩ ] i increase from NO production occurs in this bovine coronary arterial endothelium treated by endostatin. To our knowledge, these results provide the first evidence that endostatin blunts NO response to BK in the intact mature arterial endothelial cells, and this blunted NO response is not associated with inhibition of its Ca 2ϩ response. Similar to BK, A23187-induced NO production was also blocked by endostatin with no changes in the Ca 2ϩ response. These results suggest that the effect of endostatin is not only specific for BK-induced response, but it as a general mechanism may affect all agonistinduced NO responses in the endothelium.
With regard to the effect of endostatin on [Ca 2ϩ ] i , a previous study in cultured aortic endothelial cells has shown that endostatin acutely increases [Ca 2ϩ ] i through D-myo-inositol-1,4,5-trisphosphate-sensitive Ca 2ϩ release and extracellular Ca 2ϩ entry, whereas overnight treatment with endostatin attenuated the increase in [Ca 2ϩ ] i induced by VEGF or FGF-2 (13). Although the cultured endothelial cells used in that study may behave differently to the intact in situ endothelial cells used in the present studies, we did not demonstrate any effect of endostatin on basal Ca 2ϩ level in cultured coronary arterial endothelial cells. Therefore, the difference in preparations used in our study (intact endothelium) and those previous studies seemed not to be the determinant for different action of endostatin on basal Ca 2ϩ levels in the endothelium. Another possible explanation for this difference may be related to different vascular beds used in both studies (coronary vs. aorta).
One of the important findings of the present study was that endostatin attenuated BK-induced NO increase but it had no effect on the BK-induced Ca 2ϩ transient in endothelial cells. BK activates its receptors on vascular endothelial cells and subsequently causes intracellular Ca 2ϩ mobilization and stimulation of endothelial NOS activity through a calmodulindependent mechanism (35) . This Ca 2ϩ -dependent activation of NOS in endothelial cells importantly contributes to NO production in response to different agonists. In the present study, the uncoupling of BK-induced Ca 2ϩ increase from NO accumulation by endostatin indicates that this angiostatic peptide alters the NO levels in the endothelium through a Ca 2ϩ -independent mechanism. By measuring the conversion rate of [ 3 H]arginine to [ 3 H]citrulline, endostatin was found to have no effect on NOS activity in bovine coronary arterial endothelial cells. This suggests that this peptide does not directly inhibit NOS enzyme activity to decrease NO levels.
Recently, the mechanism mediating the actions of endostatin on cell apoptosis or angiogenesis has been extensively studied (29) . Several cell surface proteins, such as glypicans and integrins, may participate in the mediation or regulation of endostatin-induced actions (15, 31, 32) . Glypicans, which are classified as a family of cell surface glycosyl-phosphatidylinositol anchored heparan sulfate proteoglycans, act as low-affinity endostatin receptors and cointeract with yet unidentified high-affinity receptors through protein-protein interaction to transmit endostatin signaling (15) . Moreover, cell surface integrins, especially with ␣ v ␤ 1 , a major fibronectin receptor in endothelial cells, have been implicated in the action of endostatin (31) . Binding of the integrins to extracellular ligands may initiate a series of events, including integrins clustering, cytoskeletal reorganization, and other downstream signaling events (29, 36) . In addition, endostatin exerts its antimigratory or antiangiogenetic action by inhibition of matrix metalloproteinase-2 activity, direct interaction with cell surface VEGF receptors, protein phosphorylation related to phosphatase PP2A activity or tyrosine kinase activity, and downregulation of growth-and apoptosis-related genes and antiapoptotic protein levels (7, 17, 21, 33, 34) . However, most of these mechanisms are thought to contribute to inhibition of cell growth or apoptosis induced by endostatin. There is no evidence indicating that these mechanisms contribute to the NO decrease induced by endostatin in endothelial cells.
Given the potent apoptotic action of endostatin in endothelial cells, it is possible that its action is related to the signaling of death receptors. Recent studies have indicated that various death receptor ligands or stimulators such as TNF-␣, Fas L, and angiostatin may induce apoptosis by activating ceramide production in addition to caspase activation (12, 28) . These stimuli could stimulate SMase activity to produce ceramide and thereby induce cell apoptosis (28) . More recently, work in our laboratory and by others has demonstrated that ceramide increase by TNF-␣ activated NAD(P)H oxidase to produce O 2 Ϫ ⅐, thereby producing endothelial dysfunction and reducing NO-mediated vasodilation in isolated small bovine coronary arteries (38, 40) . Based on these previous results, we hypothesized that endostatin may activate SMases and in this way stimulate ceramide production, which activates NAD(P)H oxidase for O 2 Ϫ ⅐ generation, thereby decreasing NO levels and producing endothelial dysfunction. To test this hypothesis, we first examined whether endostatin increases the ceramide level in endothelial cells. With the use of TLC analysis, it was found that endostatin produced a time-dependent increase in endothelial ceramide levels, suggesting that the ceramide-mediated signaling is involved in the actions of endostatin. Interestingly, a recent study has shown that another angiogenesis inhibitor angiostatin acutely increased ceramide in the endothelial cells, which is associated with free radical production (12) . Taken together, it appears that ceramide serves as a general signaling molecule mediating the acute response of angiogenesis inhib-itory peptides such as endostatin and angiostatin, especially during the early stage of their actions.
To explore the mechanism by which ceramide level is increased by endostatin, we examined the activities of SMases in these endothelial cells. Endostatin was found to produce a rapid activation of endothelial A-SMase but not N-SMase. Desipramine, a selective A-SMase inhibitor, concentration dependently decreased endostatin-stimulated ceramide production, suggesting that an A-SMase-ceramide pathway mediates the early response to endostatin. In previous studies, A-SMase was found to translocate from cytosol to sphingomylin-enriched membrane in response to various stimuli such as Fas L, whereby it is activated to produce ceramide (11) . Ceramide then serves as a signaling molecule to stimulate the activities of a variety of enzymes such as NAD(P)H oxidase and increase intracellular oxidative stress, resulting in impairment of many cellular functions. Previous studies in our laboratory have demonstrated that ceramide can activate NAD(P)H oxidase and thereby increase O 2 Ϫ ⅐ production, leading to endothelial dysfunction in the coronary circulation (40) . Therefore, it is possible that endostatin increases intracellular O 2 Ϫ ⅐ through this ceramide-NAD(P)H oxidase pathway in the endothelium.
With the use of DHE as a fluorescence indicator for O 2 Ϫ ⅐, endostatin was found to induce a time-dependent increase in DHE-O 2 Ϫ ⅐ fluorescence in the intact endothelium of coronary arteries. This endostatin-induced O 2 Ϫ ⅐ production was attenuated by a SOD mimetic tiron. To our knowledge, these results provide the first direct evidence that intracellular O 2 Ϫ ⅐ levels increased in the intact endothelium with endostatin. In our previous studies, ceramide activated NAD(P)H oxidase to increase O 2 Ϫ ⅐ production without an effect on other O 2 Ϫ ⅐-generating systems such as mitochondrial electron transport chain enzymes (10, 40) . Therefore, we wondered whether the action to produce O 2 Ϫ ⅐ is associated with ceramide-mediated activation of NAD(P)H oxidase. With the use of an A-SMase inhibitor desipramine or a NAD(P)H oxidase inhibitor apocynin, endostatin-induced increase in O 2 Ϫ ⅐ production in the intact endothelium could be blocked. By biochemical analysis, NAD(P)H oxidase activity was also found significantly increased in endothelial cells pretreated with endostatin in a time-dependent manner, which was markedly inhibited by desipramine and apocynin. Taken together, these results suggest that endostatin is a potent stimulus for the production of O 2 Ϫ ⅐ in coronary endothelial cells through ceramide-mediated activation of NAD(P)H oxidase.
It is well documented that O 2 Ϫ ⅐ reduces NO bioavailability through a rapid formation of peroxynitrite and thereby results in the impairment of endothelial function (2) . To further address whether endostatin decreases NO by enhanced intracellular O 2 Ϫ ⅐ production, we explored the possibility that O 2 Ϫ ⅐ scavenging restores BK-induced NO production in the endostatin-treated endothelium. The SOD mimetic tiron reversed the inhibitory effect of endostatin on BK-induced NO production without affecting the Ca 2ϩ response. Tiron completely blocked endostatin-induced production of O 2 Ϫ ⅐. Similar to tiron, the NAD(P)H oxidase inhibitor apocynin also recovered the NO response of the endothelium to BK. These results further confirm that NAD(P)H oxidase-derived O 2 Ϫ ⅐ is involved in endostatin-induced decrease in NO response to agonists in coronary arterial endothelium. This reduced endothelial NO response may result in impairment of endothelial-dependent vasodilation (20) .
In summary, the present study demonstrated that 1) a relatively short-time treatment of endostatin blocked BK-induced NO increase in the intact endothelium; 2) endostatin increased A-SMase activity and intracellular ceramide levels; and 3) endostatin stimulated production of intracellular O 2 Ϫ ⅐ level through activation of NAD(P)H oxidase in coronary arterial endothelial cells. It is concluded that endostatin activates A-SMase to produce ceramide, which enhances intracellular O 2 Ϫ ⅐ production and consequently impairs endothelial NO response to BK in coronary arteries.
